8-K: Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results, Advances Pipeline

Amylyx Pharmaceuticals announced its Q1 2025 financial results, highlighting progress in clinical trials for avexitide, AMX0035, and AMX0114, and reporting a cash runway through the end of 2026.

Summary

• Amylyx Pharmaceuticals reported its financial results for the first quarter ended March 31, 2025.
• The company is progressing with its pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia (PBH), expecting completion of enrollment in 2025 and topline data in the first half of 2026.
• Amylyx has begun dosing in the Phase 1 LUMINA trial of AMX0114 for amyotrophic lateral sclerosis (ALS), with early cohort data expected in 2025.
• Week 48 data from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome will be presented at an upcoming conference.
• Topline data from the Phase 2b portion of the Phase 2b/3 ORION trial of AMX0035 for progressive supranuclear palsy (PSP) are expected in the third quarter of 2025.
• The company's cash, cash equivalents, and marketable securities totaled $204.1 million as of March 31, 2025, providing a cash runway through the end of 2026.
• Net loss for the quarter was $35.9 million, or $0.42 per share, compared to a net loss of $118.8 million, or $1.75 per share, for the same period in 2024.
• Research and development expenses for the first quarter of 2025 were $22.1 million, compared to $36.6 million for the same period in 2024.
• Selling, general, and administrative expenses for the first quarter of 2025 were $15.7 million, compared to $57.8 million for the same period in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to progress in clinical trials, a strong cash position, and reduced losses compared to the previous year, although the company is still operating at a loss.

Positives

• Amylyx has a strong cash position of $204.1 million, expected to fund operations through the end of 2026.
• The company is making progress across its pipeline with multiple clinical trials underway.
• Net loss per share decreased significantly from $1.75 in Q1 2024 to $0.42 in Q1 2025.
• Research and development expenses decreased from $36.6 million in Q1 2024 to $22.1 million in Q1 2025.
• Selling, general, and administrative expenses decreased from $57.8 million in Q1 2024 to $15.7 million in Q1 2025.

Negatives

• The company reported a net loss of $35.9 million for the first quarter of 2025.
• The cash position at March 31, 2025 reflects payments of $6.0 million in the first quarter of 2025 related to product rebates and the settlement of purchase commitments for AMX0035 that were established prior to the voluntary discontinuation of sales of RELYVRIO/ALBRIOZA in April 2024.

Risks

• The success of Amylyx's program development activities is subject to risks and uncertainties.
• The company's ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies is uncertain.
• Global macroeconomic uncertainty, geopolitical instability, and public health events could impact Amylyx's operations.
• The company is dependent on the success of its clinical trials and regulatory approvals for its investigational therapies.

Future Outlook

Amylyx expects completion of enrollment in the Phase 3 LUCIDITY trial in 2025, with topline data in the first half of 2026, and anticipates a commercial launch in 2027 if approved; the company also anticipates topline data from the Phase 2b portion of the Phase 2b/3 ORION trial in the third quarter of 2025 and early cohort data from the Phase 1 LUMINA trial in 2025, with a cash runway through the end of 2026.

Management Comments

• We remain focused on avexitide and continue to expect completion of enrollment in 2025 and topline data in the first half of 2026, said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx.
• We also made important progress in dosing the first patient in our Phase 1 LUMINA trial of AMX0114 in ALS, with early cohort data expected later this year.
• With our momentum so far this year and current anticipated cash runway through the end of 2026, we remain confident in achieving our current goals and look forward to our upcoming milestones.

Industry Context

Amylyx is focused on developing therapies for neurodegenerative and endocrine diseases with high unmet needs, such as ALS, PSP, Wolfram syndrome, and PBH, which aligns with the broader industry trend of targeting rare and underserved diseases.

Comparison to Industry Standards

• The company's focus on rare diseases aligns with companies like BioMarin Pharmaceutical and Sarepta Therapeutics, which specialize in developing therapies for genetic disorders.
• The Phase 3 LUCIDITY trial for PBH is comparable to other late-stage clinical trials in the metabolic disease space, such as those conducted by Zealand Pharma for congenital hyperinsulinism.
• Amylyx's cash runway through the end of 2026 is a positive indicator of financial stability, similar to other biotech companies with successful fundraising rounds, such as CRISPR Therapeutics and Vertex Pharmaceuticals.

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and strong cash position are positive for shareholders.
• Employees: Continued investment in research and development provides job security and growth opportunities for employees.
• Patients: Advancements in clinical trials offer hope for new treatments for diseases with high unmet needs.
• Suppliers: Ongoing clinical trials and research activities provide business opportunities for suppliers.

Next Steps

• Complete enrollment for the Phase 3 LUCIDITY clinical trial of avexitide in PBH in 2025.
• Share Week 48 data from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome at the Joint Congress of the European Society for Pediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) on May 10-13.
• Present additional data from the Phase 2 PREVENT and Phase 2b trials of avexitide in PBH at the Endocrine Society's annual meeting (ENDO) 2025 on July 12-15.
• Announce unblinded analysis of the Phase 2b portion of the Phase 2b/3 ORION trial evaluating AMX0035 for progressive supranuclear palsy (PSP) in the third quarter of 2025.
• Share early cohort data from the Phase 1 LUMINA clinical trial of AMX0114 in ALS in 2025.
• Anticipate data readout for the Phase 3 LUCIDITY clinical trial of avexitide in PBH in the first half of 2026.

Key Dates

Keywords

Amylyx Pharmaceuticals, avexitide, AMX0035, AMX0114, LUCIDITY, HELIOS, LUMINA, ORION, Post-bariatric hypoglycemia, Wolfram syndrome, ALS, PSP, Clinical trials, Financial results